Evidence map›Paper›PMID 38434845›Full record

ArticleACS omega2024

Generalizability Improvement of Interpretable Symbolic Regression Models for Quantitative Structure-Activity Relationships.

Raku Shirasawa, Katsushi Takaki, Tomoyuki Miyao

Abstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Raku ShirasawaGraduate School of Science and Technology, Nara Institute of Science and Technology, 8916-5 Takayama-cho, Ikoma, Nara 630-0192, Japan.
Katsushi TakakiGraduate School of Science and Technology, Nara Institute of Science and Technology, 8916-5 Takayama-cho, Ikoma, Nara 630-0192, Japan.
Tomoyuki MiyaoGraduate School of Science and Technology, Nara Institute of Science and Technology, 8916-5 Takayama-cho, Ikoma, Nara 630-0192, Japan.ORCID https://orcid.org/0000-0002-8769-2702

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the pursuit of optimal quantitative structure-activity relationship (QSAR) models, two key factors are paramount: the robustness of predictive ability and the interpretability of the model. Symbolic regression (SR) searches for the mathematical expressions that explain a training data set. Thus, the models provided by SR are globally interpretable. We previously proposed an SR method that can generate interpretable expressions by humans. This study introduces an enhanced symbolic regression method, termed filter-induced genetic programming 2 (FIGP2), as an extension of our previously proposed SR method. FIGP2 is designed to improve the generalizability of SR models and to be applicable to data sets in which cost-intensive descriptors are employed. The FIGP2 method incorporates two major improvements: a modified domain filter to eradicate diverging expressions based on optimal calculation and the introduction of a stability metric to penalize expressions that would lead to overfitting. Our retrospective comparative analysis using 12 structure-activity relationship data sets revealed that FIGP2 surpassed the previously proposed SR method and conventional modeling methods, such as support vector regression and multivariate linear regression in terms of predictive performance. Generated mathematical expressions by FIGP2 were relatively simple and not divergent in the domain of function. Taken together, FIGP2 can be used for making interpretable regression models with predictive ability.

Identifiers

PMID38434845
PMCPMC10905595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.